



PRESS RELEASE

Lelystad, the Netherlands, 1 June 2010

Sale of Dutch Allergy Division to ALK-Abelló:

- **Publication of Shareholder Circular on proposed divestment of Dutch Allergy Division to ALK-Abelló**
- **Fornix intends to distribute the net proceeds as part of the interim dividend 2010 to its shareholders**
- **Future strategy of Fornix will be focused completely on the growth of its Medical Aids Division**

Reference is made to the press release dated 26 April 2010 of Fornix BioSciences N.V. (**Fornix**) announcing the proposed sale of the Dutch activities of Fornix' Allergy Division (Artu Biologicals) to ALK-Abelló and related arrangements (the **Transaction**). Fornix announces that today it will publish a Shareholder Circular regarding the proposed Transaction as well as the agenda for the Extraordinary General Meeting of Shareholders (**EGM**) to be held on Tuesday 29 June 2010. The purpose of the EGM is to obtain approval of the Transaction from Fornix' general meeting of shareholders.

The Management Board and Supervisory Board of Fornix unanimously recommend that Fornix' shareholders vote in favour of the resolution to be proposed at the EGM to approve the Transaction. The reasons for doing so are detailed in the Shareholder Circular together with a description of and further background to the Transaction. The Shareholder Circular can be retrieved from www.fornix.nl (as from 12.00 hours CET today) or obtained, free of charge, from Fornix as well as from Kempen & Co N.V. (Beethovenstraat 11 in Amsterdam).

Fornix intends to distribute to its shareholders the net proceeds from the Transaction in cash as part of its annual interim dividend 2010. Fornix estimates that such net proceeds will amount to EUR 2.30 per share. Shareholders should note that the definitive amount can be determined only after completion of the Transaction. In addition, Fornix expects to pay an interim dividend in cash to its shareholders based on the estimated results of the first half of the financial year 2010, which includes the results of the Allergy Division for that period. This interim dividend will be equal to the previous two years (September 2008 and 2009: EUR 0.65 per share). Fornix will make further announcements regarding this total interim-dividend in August 2010.

Upon completion of the Transaction, Fornix will consist of its Medical Aids Division (Laprolan) and Artu Biologicals Deutschland GmbH & Co. Fornix' future strategy will be focused completely on the growth of the company in the broader field of medical devices.



As current activities are relatively modest, Fornix will put all efforts into exploring organic and acquisitive growth opportunities in order to gain additional critical mass. The Management Board and the Supervisory Board are committed to and support the abovementioned future strategy.

For more information, please contact: **Fornix BioSciences N.V.**
Mr C.L. Bergman, CEO
Tel. (0320) 26 77 99
Website: www.fornix.nl

END OF PRESS RELEASE



About Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) which engages mainly in the development and sale of diagnostic and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables.

Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has 138 employees and operates mainly in the Netherlands and Germany. Its activities are conducted by two divisions, the Allergy Division consisting of Artu Biologicals Europe and the Medical Aids Division. The activities of Artu Biologicals Deutschland are conducted separately from these two divisions.

The Allergy Division focuses on the development, production and sale of a wide range of patient-friendly immunotherapeutic products including the Oralgen[®] and Igevac[®] brands. These products are administered in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house-dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies on the effectiveness and safety of the various products. Clinical research should over time lead to the registration of the company's most important allergen products Oralgen[®] Grass Pollen, Tree Pollen and House-dust mite. In the coming years, the company intends to increase its focus on allergen products and to expand its position in the growing immunotherapy market in Europe.

Artu Biologicals Deutschland in Hamburg carries a growing range of medical aids in Germany on an exclusive basis. The Oralgen[®] equivalent Igevac[®] is also distributed in this market on a named-patient basis.

The Medical Aids Division consists of Laprolan, located in Beuningen. The division focuses on the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.